Risk factors

Gossamer Bio (GOSS) risk factors

Item 1A of every Gossamer Bio, Inc. 10-K on file, and what changed from one year to the next.

Open GOSS in Gloomberb →
  • FY2025 10-K risk factors

    78 risks, 11 new, 5 dropped, 22 reworded since the prior year. PROSERA missed its primary endpoint, putting seralutinib’s FDA path, further trials, financing needs, and commercialization in doubt.

    Filed Mar 17, 2026
  • FY2024 10-K risk factors

    72 risks. Company is pre-revenue and clinical-stage, relying heavily on the success, financing, and clinical trials of its lead product candidate, seralutinib.

    Filed Mar 13, 2025